5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
about
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.Myeloid leukemia: are we getting better?Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia.Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge.Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.Hypomethylating Agents as a Therapy for AML.Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center.Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient.Treatment of relapsed/refractory acute myeloid leukaemia in adults.Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemiaA phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
P2860
Q33437313-89ED23AC-092F-4F8F-A6FF-AE5DF4D3A066Q35054842-A8878621-D9D7-4377-94F7-E3F9F517B2F2Q35546759-0AAE9FA5-6D36-4365-99CE-3D59AAC73E2EQ35691397-28815B23-AAC6-4BC0-BD0D-626B840EFE64Q37429089-A6065938-4868-471F-8DC0-01A65E033FE4Q37624593-9DD3B083-828E-4DEB-AB74-EEC93A23E72DQ38195065-D2FECF8C-51A4-432B-921B-BAC255CA3A8FQ38569175-37E789E9-F47C-4FBE-A414-287FF26F827AQ38911864-C4DC2879-A376-4CC2-8C31-6FED2FF51E67Q38917137-A27193ED-7864-45D9-803D-C767EF6D071FQ40236553-D1A2CDF5-0CBA-4FE9-8FBD-92168DE367FBQ40438036-06A1AC03-54F8-4AAA-BE21-67EBB5E15A0BQ42550846-51DC16D6-2784-4316-81D4-93A7681A6348Q42941264-0191E5DB-AFA1-4537-9610-42D5EC94F234Q47741553-E50107C0-28A1-4B22-B8D3-0C00296692C7Q57167105-DA695105-7596-4AF4-B56C-04377C3F5D1DQ57169390-311819DC-0A82-4B59-A91E-53B346026224
P2860
5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
5-Azacytidine treatment for re ...... after intensive chemotherapy.
@en
5-Azacytidine treatment for re ...... after intensive chemotherapy.
@nl
type
label
5-Azacytidine treatment for re ...... after intensive chemotherapy.
@en
5-Azacytidine treatment for re ...... after intensive chemotherapy.
@nl
prefLabel
5-Azacytidine treatment for re ...... after intensive chemotherapy.
@en
5-Azacytidine treatment for re ...... after intensive chemotherapy.
@nl
P2093
P2860
P356
P1476
5-Azacytidine treatment for re ...... after intensive chemotherapy.
@en
P2093
Amandine Charbonnier
Berengere Gruson
Bruno Royer
Emilie Lemasle
Jean-Pierre Marolleau
Lavinia Merlusca
Patrick Votte
Sarah Ivanoff
Veronique Harrivel
P2860
P304
P356
10.1002/AJH.23464
P577
2013-05-30T00:00:00Z